Liquidia (NASDAQ:LQDA) Insider Rajeev Saggar Sells 50,000 Shares

Liquidia Corporation (NASDAQ:LQDA) insider Rajeev Saggar sold 50,000 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $74.06, for a total transaction of $3,703,000.00. Following the completion of the sale, the insider owned 142,265 shares of the company’s stock, valued at approximately $10,536,145.90. This trade represents a 26.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Rajeev Saggar also recently made the following trade(s):

• On Monday, August 17th, Rajeev Saggar sold 29,534 shares of Liquidia stock. The stock was sold at an average price of $76.84, for a total transaction of $2,269,392.56.
• On Monday, July 13th, Rajeev Saggar sold 9,926 shares of Liquidia stock. The shares were sold at an average price of $71.51, for a total transaction of $709,808.26.

Liquidia Price Performance

Shares of NASDAQ:LQDA opened at $75.33 on Thursday. The company has a 50-day simple moving average of $79.35 and a 200-day simple moving average of $55.93. Liquidia Corporation has a one year low of $21.15 and a one year high of $93.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. The stock has a market capitalization of $6.74 billion, a price-to-earnings ratio of 54.99 and a beta of 0.58.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The business had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. During the same quarter last year, the company posted ($0.49) EPS. Liquidia’s quarterly revenue was up 1842.1% on a year-over-year basis. On average, analysts predict that Liquidia Corporation will post 2.57 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Needham & Company LLC lifted their target price on Liquidia from $70.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Royal Bank Of Canada set a $130.00 price target on Liquidia in a research note on Friday, July 24th. Lifesci Capital downgraded Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 price target for the company. in a report on Wednesday, August 12th. BTIG Research lifted their price objective on shares of Liquidia from $109.00 to $111.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $98.08.

Hedge Funds Weigh In On Liquidia

A number of institutional investors have recently made changes to their positions in LQDA. Northwestern Mutual Wealth Management Co. acquired a new position in Liquidia in the 4th quarter valued at $25,000. NewEdge Advisors LLC purchased a new position in shares of Liquidia during the 2nd quarter worth $25,000. Covestor Ltd boosted its holdings in shares of Liquidia by 41.9% during the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after purchasing an additional 359 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Liquidia by 281.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock worth $83,000 after purchasing an additional 4,927 shares during the last quarter. Finally, Globeflex Capital L P purchased a new stake in shares of Liquidia in the second quarter valued at $175,000. 64.54% of the stock is owned by institutional investors and hedge funds.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).